AI Company Enters Into Evaluation Agreement With Pfizer

• AtomWise raised $45 million in Series A in March of 2018
• Partners Include: Merck, Abbvie, and Bayer

Atomwise Inc., a leader in Artificial Intelligence (AI) for drug discovery and design, has entered into an evaluation agreement with Pfizer Inc. (NYSE: PFE). Pfizer will evaluate Atomwise’s platform to identify potential drug candidates for up to three target proteins selected by Pfizer.